Gyre Therapeutics (GYRE) Financials

$5.94 -0.12 (-1.98%)

Closing price 05/26/2026 04:00 PM Eastern

Extended Trading

$5.98 +0.04 (+0.64%)

As of 07:44 AM Eastern

Annual Income Statements for Gyre Therapeutics

This table shows Gyre Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-15	-17	-26	-30	-55	-56	-88	2.30	-93	12	5.03
Consolidated Net Income / (Loss)	-15	-17	-22	-30	-55	-56	-88	4.31	-85	18	9.88
Net Income / (Loss) Continuing Operations	-15	-17	-22	-30	-55	-56	-88	4.31	-85	18	9.88
Total Pre-Tax Income	-15	-17	-22	-30	-55	-56	-88	9.41	-77	23	14
Total Operating Income	-14	-20	-22	-34	-57	-57	-88	9.20	-67	16	11
Total Gross Profit	1.75	0.40	1.02	0.01	0.00	12	-0.04	97	109	102	111
Total Revenue	1.75	0.40	1.02	0.01	0.00	21	7.34	102	113	106	117
Operating Revenue	1.75	0.40	1.02	0.01	0.00	21	7.34	102	113	106	117
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	9.16	7.38	4.79	4.64	3.88	5.42
Operating Cost of Revenue	-	-	-	-	0.00	9.16	7.38	4.79	4.64	3.88	5.42
Total Operating Expenses	16	21	23	34	57	69	88	88	176	86	100
Selling, General & Admin Expense	9.59	9.26	9.99	12	13	16	19	17	15	16	21
Marketing Expense	-	-	-	-	-	-	-	54	61	58	65
Research & Development Expense	5.96	12	13	21	44	53	69	17	97	12	14
Other Special Charges / (Income)	-	-	-	-	-	-	0.00	0.00	0.63	0.07	0.00
Total Other Income / (Expense), net	-0.96	3.47	0.26	3.77	2.10	1.13	-0.04	0.21	-9.74	7.06	2.95
Interest Expense	0.96	-3.47	-0.26	-3.77	-2.10	-1.13	0.04	-0.73	-1.04	-1.55	-1.75
Other Income / (Expense), net	-	-	-	-	-	-	-	-0.52	-11	5.51	1.20
Income Tax Expense	-	-	-	-	-	-	0.00	5.10	8.52	5.32	4.56
Net Income / (Loss) Attributable to Noncontrolling Interest	-	-	-	-	-	-	-	2.01	7.45	5.81	4.85
Basic Earnings per Share	($49.99)	($21.75)	($7.45)	($2.68)	($4.60)	($2.93)	($2.87)	$0.04	($1.41)	$0.14	$0.06
Weighted Average Basic Shares Outstanding	295.27K	779.17K	3.42M	11.21M	12.00M	19.18M	30.64M	63.59M	65.83M	85.09M	89.34M
Diluted Earnings per Share	($49.99)	($21.75)	($7.45)	($2.68)	($4.60)	($2.93)	($2.87)	$0.03	($1.41)	$0.05	$0.02
Weighted Average Diluted Shares Outstanding	295.27K	779.17K	3.42M	11.21M	12.00M	19.18M	30.64M	75.69M	65.83M	102.29M	103.18M
Weighted Average Basic & Diluted Shares Outstanding	295.27K	779.17K	3.42M	11.21M	12.00M	19.18M	30.64M	37.76M	85.42M	93.61M	96.96M

This table shows Gyre Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	3.98	-101	7.53	3.53	1.12	-0.10	2.70	0.44	3.61	-1.72	-8.69
Consolidated Net Income / (Loss)	7.51	-101	9.94	4.54	2.86	0.57	3.73	1.58	5.94	-1.37	-9.86
Net Income / (Loss) Continuing Operations	7.51	-101	9.94	4.54	2.86	0.57	3.73	1.58	5.94	-1.37	-9.86
Total Pre-Tax Income	11	-100	12	6.04	3.93	0.77	4.64	2.24	7.63	-0.07	-9.24
Total Operating Income	13	-92	8.07	3.19	4.23	0.60	2.27	2.17	6.93	0.12	-9.36
Total Gross Profit	31	26	26	24	25	27	21	26	29	35	21
Total Revenue	32	27	27	25	25	28	22	27	31	37	23
Operating Revenue	32	27	27	25	25	28	22	27	31	37	23
Total Cost of Revenue	1.18	1.25	0.98	0.77	0.96	1.18	0.89	1.15	1.63	1.74	1.23
Operating Cost of Revenue	1.18	1.25	0.98	0.77	0.96	1.18	0.89	1.15	1.63	1.74	1.23
Total Operating Expenses	19	117	18	21	20	26	19	23	22	35	31
Selling, General & Admin Expense	1.16	10	3.40	3.42	3.82	5.46	4.96	4.83	4.32	6.70	7.22
Marketing Expense	14	16	13	14	14	17	11	15	15	24	14
Research & Development Expense	3.01	88	2.18	3.36	2.78	3.71	3.10	3.43	2.36	4.82	6.74
Other Operating Expenses / (Income)	-	-	-	-	-	-	0.00	-	-	-	2.55
Total Other Income / (Expense), net	-1.05	-9.17	4.41	2.84	-0.30	0.11	2.36	0.07	0.70	-0.18	0.12
Other Income / (Expense), net	-1.33	-9.50	4.41	2.84	-0.30	-0.24	2.36	0.07	0.70	-1.93	0.12
Income Tax Expense	3.68	0.70	2.55	1.50	1.07	0.20	0.90	0.66	1.69	1.30	0.62
Net Income / (Loss) Attributable to Noncontrolling Interest	3.53	0.03	2.40	1.01	1.73	0.67	1.04	1.13	2.33	0.36	-1.17
Basic Earnings per Share	$0.06	($1.54)	$0.09	$0.04	$0.01	-	$0.03	$0.00	$0.04	($0.02)	($0.10)
Weighted Average Basic Shares Outstanding	63.59M	65.83M	83.27M	85.50M	85.64M	85.09M	86.42M	89.12M	90.85M	89.34M	91.32M
Diluted Earnings per Share	$0.05	($1.51)	$0.03	$0.01	$0.01	-	$0.00	$0.00	$0.03	($0.02)	($0.10)
Weighted Average Diluted Shares Outstanding	78.90M	65.83M	102.59M	102.21M	102.64M	102.29M	101.97M	102.70M	103.97M	103.18M	91.34M
Weighted Average Basic & Diluted Shares Outstanding	37.98M	85.42M	85.51M	93.42M	93.52M	93.61M	93.76M	96.31M	96.33M	96.96M	97.03M

This table details how cash moves in and out of Gyre Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	28	-19	-10	11	-16	15	14	-5.03	8.33	-22	25
Net Cash From Operating Activities	-19	-18	-20	-29	-44	-55	-84	11	26	-3.64	1.01
Net Cash From Continuing Operating Activities	-19	-18	-20	-29	-44	-55	-84	11	26	-3.64	0.99
Net Income / (Loss) Continuing Operations	-15	-17	-22	-30	-55	-56	-88	4.31	-85	18	9.88
Consolidated Net Income / (Loss)	-15	-17	-22	-30	-55	-56	-88	4.31	-85	18	9.88
Depreciation Expense	0.47	0.39	0.17	0.15	0.15	0.14	0.29	1.09	1.07	1.55	2.48
Amortization Expense	-	-	-	-	-	-	-	0.04	0.04	0.04	0.04
Non-Cash Adjustments To Reconcile Net Income	1.43	-2.75	0.88	2.72	3.20	3.63	3.41	14	105	-11	4.13
Changes in Operating Assets and Liabilities, net	-6.26	0.84	0.57	-1.37	8.22	-2.57	0.48	-8.64	4.76	-13	-16
Net Cash From Investing Activities	37	-1.31	-11	-71	27	9.66	48	-14	-20	-20	-0.47
Net Cash From Continuing Investing Activities	37	-1.31	-11	-71	27	9.66	48	-14	-20	-20	-0.47
Purchase of Property, Plant & Equipment	-0.27	-0.47	-0.02	-0.38	-	-	-0.84	-4.99	-8.52	-2.32	-1.19
Acquisitions	-	-	-	-	-	-	-	-1.35	-1.19	-2.50	-0.73
Sale of Property, Plant & Equipment	0.00	2.56	-	-	-	-	0.00	0.00	0.66	0.40	0.03
Sale and/or Maturity of Investments	14	10	14	128	157	108	49	-	-	0.00	15
Other Investing Activities, net	24	-0.01	-	-	-	-	0.00	-7.48	-16	-15	-14
Net Cash From Financing Activities	9.31	0.95	21	111	0.33	60	50	0.00	2.50	2.10	24
Net Cash From Continuing Financing Activities	9.31	0.95	21	111	0.33	60	50	0.00	2.50	2.10	24
Repayment of Debt	-3.02	-14	-14	-5.08	-	-	-	-	-	-0.54	-1.49
Issuance of Common Equity	0.00	0.96	5.34	-	0.33	60	49	-	0.00	0.77	24
Other Financing Activities, net	0.01	0.00	12	9.65	-	-	0.30	-	0.00	1.87	2.36
Effect of Exchange Rate Changes	-	-	-	-	-	-	-	-1.89	-0.30	-0.27	0.34
Cash Income Taxes Paid	-	-	-	-	-	-	-	6.31	6.35	8.52	5.62

This table details how cash moves in and out of Gyre Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	2.35	7.43	-3.72	-14	-0.23	-4.05	3.23	21	3.91	-3.33	0.43
Net Cash From Operating Activities	7.58	3.36	2.88	-5.49	1.73	-2.76	-0.13	2.09	4.68	-5.63	3.18
Net Cash From Continuing Operating Activities	7.58	3.36	2.88	-5.49	1.73	-2.76	-0.13	2.11	4.65	-5.63	3.18
Net Income / (Loss) Continuing Operations	7.51	-101	9.94	4.54	2.86	0.57	3.73	1.58	5.94	-1.37	-9.86
Consolidated Net Income / (Loss)	7.51	-101	9.94	4.54	2.86	0.57	3.73	1.58	5.94	-1.37	-9.86
Depreciation Expense	0.19	0.30	0.42	0.23	0.45	0.46	0.54	0.64	0.65	0.66	0.67
Amortization Expense	0.01	0.01	0.00	0.01	0.01	0.01	0.00	-	-	-	0.00
Non-Cash Adjustments To Reconcile Net Income	0.69	104	-4.36	-2.67	0.15	-3.61	1.41	2.12	0.87	-0.25	5.49
Changes in Operating Assets and Liabilities, net	-0.82	0.06	-3.10	-7.60	-1.73	-0.18	-5.81	-2.23	-2.81	-4.70	6.87
Net Cash From Investing Activities	-5.40	1.34	-7.22	-8.27	-2.39	-2.00	1.97	-3.04	-1.25	1.85	-3.06
Net Cash From Continuing Investing Activities	-5.40	1.34	-7.22	-8.27	-2.39	-2.00	1.97	-3.04	-1.25	1.85	-3.06
Purchase of Property, Plant & Equipment	-1.97	-2.32	-0.23	-1.46	-0.69	0.07	-0.12	-0.26	-0.67	-0.14	-0.18
Acquisitions	-0.00	-1.13	0.00	-	-0.00	-2.50	-0.70	-0.02	-0.02	0.00	-0.01
Purchase of Investments	-	-	0.00	-	-	-	0.00	-	-	-	0.00
Sale of Property, Plant & Equipment	0.36	0.17	0.05	0.22	-0.01	0.14	0.00	0.02	-	0.01	0.01
Sale and/or Maturity of Investments	-	-	0.00	-	-	-	11	-	-	4.24	10
Other Investing Activities, net	-2.79	-1.97	-7.04	-7.04	-1.69	0.29	-8.40	-2.78	-	-2.83	-13
Net Cash From Financing Activities	-	2.50	0.66	0.16	0.32	0.96	1.34	22	0.37	0.32	0.02
Net Cash From Continuing Financing Activities	-	2.50	0.66	0.16	0.32	0.96	1.34	22	0.37	0.32	0.02
Repayment of Debt	-	-	0.00	-	-	-	-0.12	-	-	-	0.00
Issuance of Common Equity	-	-	0.00	-	-	-	0.51	23	-	-	0.00
Other Financing Activities, net	-	-	0.66	0.28	0.37	0.02	0.96	1.03	0.05	0.32	0.02
Effect of Exchange Rate Changes	0.17	0.23	-0.05	-0.08	-	-	0.05	-	-	0.13	0.29
Cash Income Taxes Paid	1.38	0.96	1.44	5.78	0.54	0.76	3.36	0.45	0.69	1.13	1.21

This table presents Gyre Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	70	38	40	125	99	95	56	85	117	125	166
Total Current Assets	69	38	39	124	96	90	51	50	57	65	102
Cash & Equivalents	29	10	14	31	15	30	44	25	34	12	37
Short-Term Investments	3.40	6.80	18	89	61	49	2.50	-	0.00	15	15
Note & Lease Receivable	-	-	-	-	-	-	-	17	0.39	9.33	5.64
Accounts Receivable	0.49	0.03	-	-	15	3.31	1.82	0.00	16	20	31
Inventories, net	-	-	-	-	-	-	-	6.12	4.28	6.34	10
Prepaid Expenses	1.78	0.96	1.33	3.81	4.20	6.84	2.81	0.38	1.55	1.19	2.83
Plant, Property, & Equipment, net	0.70	0.44	0.28	0.39	0.30	0.43	0.97	18	23	24	24
Total Noncurrent Assets	0.13	0.13	0.13	0.54	2.18	4.90	3.22	17	36	37	40
Intangible Assets	-	-	-	-	-	-	-	0.30	0.21	0.27	4.73
Noncurrent Deferred & Refundable Income Taxes	-	-	-	-	-	-	-	4.08	4.70	5.62	6.87
Other Noncurrent Operating Assets	-	0.13	0.13	0.54	2.18	2.36	3.22	13	26	31	29
Total Liabilities & Shareholders' Equity	70	38	40	125	99	95	56	85	117	125	166
Total Liabilities	38	22	8.74	4.98	30	19	15	13	38	27	24
Total Current Liabilities	38	22	8.74	4.80	29	18	14	12	20	20	18
Accounts Payable	0.94	0.84	0.75	1.25	4.28	5.93	6.42	0.12	0.36	0.11	0.12
Accrued Expenses	0.54	0.81	1.32	2.04	7.03	6.74	4.07	9.26	12	11	14
Current Deferred & Payable Income Tax Liabilities	-	-	-	-	-	-	-	2.10	5.05	2.83	2.94
Other Current Liabilities	1.16	-	-	-	0.48	0.66	1.98	0.61	2.70	5.96	0.86
Total Noncurrent Liabilities	0.34	0.05	0.00	0.17	1.32	0.98	0.41	0.29	18	7.49	5.56
Noncurrent Deferred Revenue	0.34	0.05	0.00	0.17	-	-	-	0.12	0.21	0.93	0.85
Other Noncurrent Operating Liabilities	-	-	-	-	1.32	0.98	0.41	0.18	18	6.56	4.71
Commitments & Contingencies	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	31	16	31	120	68	76	41	72	14	98	142
Total Preferred & Common Equity	31	16	31	120	68	76	41	43	-16	63	106
Total Common Equity	31	16	31	120	68	76	41	43	-16	63	106
Common Stock	162	164	204	323	327	391	444	33	68	136	172
Retained Earnings	-131	-148	-173	-203	-259	-315	-403	7.40	-86	-73	-68
Accumulated Other Comprehensive Income / (Loss)	0.00	-0.00	0.00	-0.00	0.03	0.01	-	-0.39	-1.64	-2.60	-0.78
Other Equity Adjustments	-	-	-	-	-	-	-	2.66	3.10	3.10	3.10
Noncontrolling Interest	-	-	-	-	-	-	-	30	30	35	36

This table presents Gyre Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	31	19	12	9.96	122	121	125	130	153	159	162
Total Current Assets	30	14	7.62	5.13	63	54	55	68	91	99	92
Cash & Equivalents	23	8.10	6.92	2.23	30	16	16	15	36	40	38
Short-Term Investments	0.00	-	-	-	7.57	9.00	9.23	15	18	20	12
Note & Lease Receivable	-	-	-	-	15	19	19	2.14	0.50	0.69	3.82
Accounts Receivable	5.00	5.00	0.00	1.20	1.29	1.29	1.29	20	25	26	23
Inventories, net	-	-	-	-	4.94	5.64	6.38	7.88	8.86	8.85	11
Prepaid Expenses	2.16	0.92	0.70	1.70	1.79	1.15	1.05	8.16	2.70	2.87	3.76
Plant, Property, & Equipment, net	0.12	0.00	0.00	0.00	24	24	24	24	23	24	24
Total Noncurrent Assets	0.65	4.74	4.77	4.83	36	44	46	38	38	37	47
Intangible Assets	-	-	-	-	0.20	0.19	0.18	5.08	4.96	4.85	4.63
Noncurrent Deferred & Refundable Income Taxes	-	-	-	-	5.00	5.08	5.16	5.82	6.13	6.71	7.72
Other Noncurrent Operating Assets	0.65	0.19	0.17	0.17	26	34	36	27	27	26	34
Total Liabilities & Shareholders' Equity	31	19	12	9.96	122	121	125	130	153	159	162
Total Liabilities	1.64	11	7.40	6.45	33	28	27	25	23	22	25
Total Current Liabilities	1.64	6.84	2.79	1.78	19	16	15	19	17	16	20
Accounts Payable	0.04	0.02	0.01	0.16	0.33	0.27	0.30	0.12	0.07	0.56	0.27
Accrued Expenses	0.18	0.74	2.07	0.92	11	11	9.55	17	15	12	15
Current Deferred & Payable Income Tax Liabilities	-	-	-	-	6.47	2.26	2.84	0.57	1.08	2.65	3.13
Other Current Liabilities	0.38	5.00	0.00	0.00	1.88	2.47	1.98	1.03	0.84	0.91	0.98
Total Noncurrent Liabilities	0.00	4.55	4.61	4.66	14	12	12	6.50	6.28	6.06	5.24
Noncurrent Deferred Revenue	-	-	-	-	0.20	0.19	0.19	0.91	0.88	0.87	0.84
Other Noncurrent Operating Liabilities	0.00	4.55	4.61	4.66	14	12	12	5.59	5.40	5.19	4.40
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	29	-26	-28	3.52	89	93	98	104	129	137	137
Total Preferred & Common Equity	29	-26	-28	3.52	57	60	63	68	92	102	101
Total Common Equity	29	-26	-28	-30	57	60	63	68	92	102	101
Common Stock	400	385	385	385	133	134	134	138	162	167	175
Retained Earnings	-370	-411	-413	-415	-78	-74	-73	-71	-70	-67	-78
Accumulated Other Comprehensive Income / (Loss)	-	-	-	-	-1.74	-2.01	-0.95	-2.49	-2.29	-1.70	0.59
Other Equity Adjustments	-	-	-	-	3.10	3.10	3.10	3.10	3.10	3.10	3.65
Noncontrolling Interest	-	-	-	-	32	33	35	36	37	35	36

This table displays calculated financial ratios and metrics derived from Gyre Therapeutics' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	96,333,157.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	96,333,157.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	0.05
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Net Operating Profit after Tax (NOPAT)	-9.66	-14	-15	-24	-40	-40	-62	4.22	-47	12	7.86
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-337.38%	12.66%	5.53%
Earnings before Interest and Taxes (EBIT)	-14	-20	-22	-34	-57	-57	-88	8.69	-78	22	13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-13	-20	-22	-34	-57	-57	-88	9.82	-77	23	15
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-10	-14	-14	-25	-32	-43	-62	-49	-45	-14	-10
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-1.25	-1.06	-1.92	-0.23	-8.53	-5.83	-5.76	47	45	72	90
Increase / (Decrease) in Invested Capital	0.82	0.19	-0.86	1.69	-8.30	2.70	0.07	53	-2.08	27	18
Book Value per Share	$2.75	$1.34	$7.14	$10.04	$5.68	$3.44	$1.31	$1.35	($0.42)	$0.68	$1.10
Tangible Book Value per Share	$2.75	$1.34	$7.14	$10.04	$5.68	$3.44	$1.31	$1.34	($0.42)	$0.67	$1.05
Total Capital	65	35	36	120	68	76	41	72	78	98	142
Total Debt	34	19	5.09	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-33	-17	-33	-120	-77	-82	-47	-25	-34	-27	-52
Capital Expenditures (CapEx)	0.27	-2.10	0.02	0.38	0.00	0.00	0.84	4.99	7.85	1.91	1.16
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-1.61	-1.57	-2.32	-0.99	-9.70	-7.64	-9.54	12	3.67	19	32
Debt-free Net Working Capital (DFNWC)	65	35	35	119	67	72	37	37	37	45	84
Net Working Capital (NWC)	31	16	30	119	67	72	37	37	37	45	84
Net Nonoperating Expense (NNE)	5.10	2.65	6.29	6.38	15	16	26	-0.10	38	-5.44	-2.02
Net Nonoperating Obligations (NNO)	-33	-17	-33	-120	-77	-82	-47	-25	-34	-27	-52
Total Depreciation and Amortization (D&A)	0.47	0.39	0.17	0.15	0.15	0.14	0.29	1.13	1.11	1.59	2.52
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($49.95)	($21.75)	($7.45)	($2.68)	$0.00	($2.93)	($2.87)	($0.26)	($1.41)	$0.14	$0.06
Adjusted Weighted Average Basic Shares Outstanding	762.01K	1.00M	11.89M	11.97M	0.00	31.33M	31.48M	31.55M	65.83M	85.09M	89.34M
Adjusted Diluted Earnings per Share	($49.95)	($21.75)	($7.45)	($2.68)	$0.00	($2.93)	($2.87)	($0.26)	($1.41)	$0.05	$0.02
Adjusted Weighted Average Diluted Shares Outstanding	762.01K	1.00M	11.89M	11.97M	0.00	31.33M	31.48M	31.55M	65.83M	102.29M	103.18M
Adjusted Basic & Diluted Earnings per Share	($49.95)	($21.75)	($7.45)	($2.68)	$0.00	($2.93)	($2.87)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	295.27K	779.17K	3.42M	11.21M	0.00	19.18M	30.64M	37.76M	85.42M	93.61M	96.96M
Normalized Net Operating Profit after Tax (NOPAT)	-9.66	-14	-15	-24	-40	-40	-62	6.44	-47	13	7.86
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-

This table displays calculated financial ratios and metrics derived from Gyre Therapeutics' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	96,333,157.00	96,963,611.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	96,333,157.00	96,963,611.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-0.02	-0.09
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	-73.25%	8.99%	-13.99%	-20.45%	2.67%	-18.82%	6.13%	19.92%	-	2.09%
EBITDA Growth	326.94%	-366.92%	97.36%	1.18%	-66.81%	100.82%	-59.91%	-54.03%	89.21%	-	-265.67%
EBIT Growth	321.27%	-350.27%	99.66%	2.68%	-70.20%	100.35%	-62.86%	-62.92%	94.12%	-	-299.29%
NOPAT Growth	336.93%	-307.98%	43.37%	-23.43%	-64.10%	100.69%	-71.50%	-36.34%	75.16%	-	-457.62%
Net Income Growth	253.77%	-261.95%	135.59%	20.37%	-61.97%	100.56%	-62.42%	-65.27%	107.84%	-	-364.01%
EPS Growth	131.25%	-52.53%	0.00%	-50.00%	-80.00%	0.00%	-100.00%	-100.00%	200.00%	-	0.00%
Operating Cash Flow Growth	204.19%	-92.06%	-72.31%	-221.18%	-77.24%	-182.08%	-104.47%	138.01%	170.92%	-	2,565.12%
Free Cash Flow Firm Growth	199.06%	9.43%	-1,723.13%	-869.62%	-608.83%	57.58%	53.73%	92.18%	102.03%	-	8.73%
Invested Capital Growth	-79.49%	-4.42%	7,020.46%	3,639.73%	5,592.94%	59.53%	44.72%	10.01%	5.43%	-	17.16%
Revenue Q/Q Growth	9.25%	-15.27%	-54.09%	-7.17%	1.04%	9.35%	-20.86%	21.37%	14.17%	-	-39.46%
EBITDA Q/Q Growth	96.47%	-966.69%	116.51%	-52.37%	-35.55%	-78.53%	523.64%	-44.31%	187.53%	-	-640.28%
EBIT Q/Q Growth	104.02%	-984.70%	115.73%	-52.66%	-40.78%	-89.49%	1,194.69%	-51.72%	240.88%	-	-409.49%
NOPAT Q/Q Growth	167.47%	-848.64%	111.88%	-61.82%	25.41%	-85.70%	316.15%	-16.51%	252.44%	-	-8,027.97%
Net Income Q/Q Growth	99.20%	-1,444.57%	110.81%	-54.32%	-37.06%	-80.08%	556.24%	-57.79%	276.65%	-	-621.67%
EPS Q/Q Growth	150.00%	-3,120.00%	102.11%	-66.67%	0.00%	0.00%	0.00%	0.00%	0.00%	-	-400.00%
Operating Cash Flow Q/Q Growth	67.26%	-55.68%	-92.37%	-290.46%	131.42%	-259.79%	95.32%	1,718.60%	123.95%	-	156.53%
Free Cash Flow Firm Q/Q Growth	54.15%	-557.58%	12.03%	-48.07%	-1.91%	61.86%	19.62%	74.94%	126.48%	-	-7.04%
Invested Capital Q/Q Growth	166.86%	3,388.36%	14.35%	32.73%	7.53%	-2.25%	3.74%	0.90%	3.05%	-	-2.98%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	96.30%	95.40%	96.40%	96.95%	96.24%	95.78%	95.95%	95.70%	94.67%	-	94.55%
EBITDA Margin	36.31%	-371.38%	46.29%	23.75%	15.15%	2.97%	23.44%	10.75%	27.08%	-	-38.03%
Operating Margin	39.84%	-337.53%	29.70%	12.93%	16.61%	2.14%	10.30%	8.11%	22.66%	-	-41.54%
EBIT Margin	35.68%	-372.51%	44.73%	22.81%	13.37%	1.28%	21.01%	8.36%	24.96%	-	-41.02%
Profit (Net Income) Margin	23.44%	-371.95%	36.56%	17.99%	11.21%	2.04%	16.93%	5.89%	19.42%	-	-43.78%
Tax Burden Percent	67.13%	100.70%	79.60%	75.19%	72.67%	73.70%	80.56%	70.42%	77.81%	-	106.72%
Interest Burden Percent	97.87%	99.16%	102.70%	104.90%	115.35%	215.64%	100.00%	100.00%	100.00%	-	100.00%
Effective Tax Rate	32.87%	0.00%	20.40%	24.81%	27.33%	26.30%	19.44%	29.58%	22.19%	-	0.00%
Return on Invested Capital (ROIC)	1,326.02%	-582.67%	107.96%	32.72%	33.95%	2.86%	13.28%	8.14%	25.09%	-	-42.13%
ROIC Less NNEP Spread (ROIC-NNEP)	1,334.38%	-457.13%	92.51%	19.70%	35.57%	2.43%	7.62%	8.02%	23.80%	-	-33.82%
Return on Net Nonoperating Assets (RNNOA)	-1,027.11%	178.02%	-43.74%	-6.42%	-9.53%	-0.83%	-2.65%	-2.86%	-8.59%	-	11.17%
Return on Equity (ROE)	298.91%	-404.65%	64.22%	26.31%	24.43%	2.03%	10.63%	5.28%	16.50%	-	-30.96%
Cash Return on Invested Capital (CROIC)	-1,107.71%	-97.78%	-191.05%	-172.10%	-335.71%	-24.52%	-24.01%	0.30%	7.06%	-	-14.65%
Operating Return on Assets (OROA)	326.95%	-419.90%	73.52%	38.18%	20.77%	1.12%	16.80%	6.25%	18.81%	-	-32.91%
Return on Assets (ROA)	214.80%	-419.27%	60.10%	30.11%	17.41%	1.78%	13.53%	4.40%	14.64%	-	-35.12%
Return on Common Equity (ROCE)	-3.79%	-71.68%	20.50%	8.57%	8.00%	0.55%	6.87%	3.61%	11.55%	-	-21.74%
Return on Equity Simple (ROE_SIMPLE)	-352.60%	0.00%	-140.82%	-130.89%	-132.40%	0.00%	17.17%	0.00%	0.00%	-	0.00%
Net Operating Profit after Tax (NOPAT)	8.57	-64	6.42	2.45	3.08	0.44	1.83	1.53	5.39	0.08	-6.55
NOPAT Margin	26.74%	-236.27%	23.64%	9.72%	12.07%	1.58%	8.30%	5.71%	17.63%	-	-29.08%
Net Nonoperating Expense Percent (NNEP)	-8.36%	-125.54%	15.45%	13.02%	-1.61%	0.43%	5.66%	0.12%	1.29%	-	-8.31%
Return On Investment Capital (ROIC_SIMPLE)	-	-459.84%	-	-	-	0.45%	1.76%	1.18%	3.92%	0.06%	-4.78%
Cost of Revenue to Revenue	3.70%	4.60%	3.60%	3.05%	3.76%	4.22%	4.05%	4.30%	5.33%	-	5.45%
SG&A Expenses to Revenue	3.61%	37.04%	12.51%	13.57%	15.00%	19.60%	22.46%	18.04%	14.13%	-	32.06%
R&D to Revenue	9.39%	322.94%	8.03%	13.30%	10.89%	13.32%	14.03%	12.79%	7.73%	-	29.92%
Operating Expenses to Revenue	58.11%	430.99%	66.69%	84.29%	79.63%	93.39%	85.64%	87.59%	72.02%	-	136.09%
Earnings before Interest and Taxes (EBIT)	11	-101	12	5.75	3.41	0.36	4.64	2.24	7.63	-1.81	-9.24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	12	-101	13	5.99	3.86	0.83	5.17	2.88	8.28	-1.16	-8.57
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	26.36	16.90	18.54	17.87	10.61	7.49	7.05	-	6.67
Price to Tangible Book Value (P/TBV)	0.00	0.00	26.45	16.96	18.60	17.95	11.46	7.92	7.40	-	6.99
Price to Revenue (P/Rev)	0.10	8.60	12.91	9.14	11.15	10.70	7.18	6.74	6.70	-	5.77
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	93.64	99.67	165.45	108.03	-	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	1.07%	1.00%	0.60%	0.93%	-	0.00%
Enterprise Value to Invested Capital (EV/IC)	38.32	23.05	28.94	15.06	16.10	15.89	9.80	8.95	8.97	-	7.59
Enterprise Value to Revenue (EV/Rev)	0.26	9.14	12.86	9.21	11.25	10.78	7.24	6.58	6.47	-	5.65
Enterprise Value to EBITDA (EV/EBITDA)	13.78	0.00	0.00	0.00	0.00	49.01	46.93	55.51	43.34	-	448.92
Enterprise Value to EBIT (EV/EBIT)	25.44	0.00	0.00	0.00	0.00	52.61	52.73	67.03	50.55	-	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	91.50	92.43	95.34	74.55	-	713.04
Enterprise Value to Operating Cash Flow (EV/OCF)	0.76	40.03	81.05	123.37	477.09	0.00	0.00	725.10	178.99	-	153.21
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3,085.04	130.32	-	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Financial Leverage	-0.77	-0.39	-0.47	-0.33	-0.27	-0.34	-0.35	-0.36	-0.36	-	-0.33
Leverage Ratio	1.25	1.34	1.46	1.36	1.33	1.37	1.30	1.23	1.21	-	1.21
Compound Leverage Factor	1.22	1.32	1.50	1.42	1.53	2.95	1.30	1.23	1.21	-	1.21
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Preferred Equity to Total Capital	947.09%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Noncontrolling Interests to Total Capital	0.00%	120.17%	36.20%	35.35%	35.84%	35.65%	34.69%	28.91%	25.83%	-	26.04%
Common Equity to Total Capital	-847.09%	-20.17%	63.80%	64.65%	64.16%	64.35%	65.31%	71.09%	74.17%	-	73.96%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Altman Z-Score	-33.53	12.84	27.76	22.78	26.75	25.61	17.60	18.48	20.49	-	16.60
Noncontrolling Interest Sharing Ratio	101.27%	82.29%	68.08%	67.42%	67.26%	73.15%	35.38%	31.60%	30.01%	-	29.78%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.88	2.85	3.22	3.44	3.72	3.32	3.60	5.40	6.19	-	4.64
Quick Ratio	1.92	2.51	2.78	2.89	3.12	2.86	2.76	4.71	5.46	-	3.87
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	14	-62	-46	-68	-69	-26	-21	-5.30	1.40	-18	-19
Operating Cash Flow to CapEx	470.64%	155.77%	1,593.37%	-443.70%	247.28%	0.00%	-106.61%	877.31%	700.00%	-	1,848.84%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	9.16	1.13	1.64	1.67	1.55	0.87	0.80	0.75	0.75	-	0.80
Accounts Receivable Turnover	60.58	0.00	36.80	0.00	84.47	5.83	9.29	7.82	7.83	-	5.40
Inventory Turnover	0.00	0.89	0.00	0.00	0.00	0.73	0.59	0.58	0.64	-	0.60
Fixed Asset Turnover	0.00	5.53	9.82	0.00	0.00	4.48	4.28	4.34	4.46	-	4.97
Accounts Payable Turnover	74.18	19.44	25.95	30.31	17.17	16.78	16.81	24.44	11.29	-	29.71
Days Sales Outstanding (DSO)	6.03	0.00	9.92	0.00	4.32	62.59	39.29	46.69	46.61	-	67.63
Days Inventory Outstanding (DIO)	0.00	409.52	0.00	0.00	0.00	498.91	615.72	632.90	573.20	-	610.45
Days Payable Outstanding (DPO)	4.92	18.78	14.06	12.04	21.26	21.76	21.71	14.93	32.32	-	12.29
Cash Conversion Cycle (CCC)	1.10	390.75	-4.15	-12.04	-16.94	539.75	633.29	664.66	587.49	-	665.79
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1.29	45	51	68	73	72	74	75	77	90	87
Invested Capital Turnover	49.59	2.47	4.57	3.37	2.81	1.81	1.60	1.43	1.42	-	1.45
Increase / (Decrease) in Invested Capital	-5.00	-2.08	52	70	72	27	23	6.83	3.98	18	13
Enterprise Value (EV)	49	1,036	1,488	1,028	1,182	1,140	729	672	694	-	662
Market Capitalization	18	976	1,493	1,020	1,172	1,132	723	689	718	-	676
Book Value per Share	($0.78)	($0.42)	$0.66	$0.71	$0.68	$0.68	$0.73	$0.98	$1.06	$1.10	$1.04
Tangible Book Value per Share	($0.78)	($0.42)	$0.66	$0.70	$0.67	$0.67	$0.67	$0.93	$1.01	$1.05	$1.00
Total Capital	3.52	78	89	93	98	98	104	129	137	142	137
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-2.23	-34	-37	-25	-25	-27	-30	-54	-60	-52	-50
Capital Expenditures (CapEx)	1.61	2.16	0.18	1.24	0.70	-0.20	0.12	0.24	0.67	0.13	0.17
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1.12	3.67	5.89	13	15	19	20	20	23	32	22
Debt-free Net Working Capital (DFNWC)	3.35	37	43	38	40	45	49	74	83	84	72
Net Working Capital (NWC)	3.35	37	43	38	40	45	49	74	83	84	72
Net Nonoperating Expense (NNE)	1.06	37	-3.51	-2.09	0.22	-0.13	-1.90	-0.05	-0.55	1.45	3.31
Net Nonoperating Obligations (NNO)	-2.23	-34	-37	-25	-25	-27	-30	-54	-60	-52	-50
Total Depreciation and Amortization (D&A)	0.20	0.31	0.43	0.24	0.45	0.47	0.54	0.64	0.65	0.66	0.67
Debt-free, Cash-free Net Working Capital to Revenue	0.60%	3.23%	5.09%	11.51%	14.28%	17.59%	19.44%	19.57%	21.08%	-	18.91%
Debt-free Net Working Capital to Revenue	1.78%	32.77%	37.37%	34.00%	38.17%	42.81%	49.14%	72.77%	77.06%	-	61.46%
Net Working Capital to Revenue	1.78%	32.77%	37.37%	34.00%	38.17%	42.81%	49.14%	72.77%	77.06%	-	61.46%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.04)	($1.54)	$0.09	$0.04	$0.01	$0.00	$0.03	$0.00	$0.04	($0.02)	($0.10)
Adjusted Weighted Average Basic Shares Outstanding	37.98M	65.83M	83.27M	85.50M	85.64M	85.09M	86.42M	89.12M	90.85M	89.34M	91.32M
Adjusted Diluted Earnings per Share	($0.04)	($1.51)	$0.03	$0.01	$0.01	$0.00	$0.00	$0.00	$0.03	($0.02)	($0.10)
Adjusted Weighted Average Diluted Shares Outstanding	37.98M	65.83M	102.59M	104.33M	102.64M	102.29M	101.97M	102.70M	103.97M	103.18M	91.34M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	($0.02)	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	37.98M	85.42M	85.51M	93.42M	93.52M	93.61M	93.76M	96.31M	96.33M	96.96M	97.03M
Normalized Net Operating Profit after Tax (NOPAT)	8.92	-64	6.42	2.50	3.08	0.44	1.83	1.53	5.39	0.08	-6.55
Normalized NOPAT Margin	27.84%	-236.27%	23.64%	9.93%	12.07%	1.58%	8.30%	5.71%	17.63%	-	-29.08%
Pre Tax Income Margin	34.92%	-369.38%	45.93%	23.92%	15.42%	2.77%	21.01%	8.36%	24.96%	-	-41.02%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%

Financials Breakdown Chart

Key Financial Trends

Here are key four-year trends for Gyre Therapeutics (GYRE) based on the quarterly statements provided. The items are organized to highlight positives first, then neutral factors, and finally negatives.

2025 Q4 revenue rose to $37,195,000, up from $27,872,000 in 2024 Q4, indicating top-line growth in late 2025.
Gross profit for 2025 Q4 was $35,452,000 on $37,195,000 of revenue, implying a very favorable gross margin (around 95%).
Net income from continuing operations was positive in several 2025 quarters, including $5,936,000 in 2025 Q3 and $1,576,000 in 2025 Q2, suggesting improving profitability trends within the year.
Liquidity improved in 2025 Q2 due to equity financing: issuance of common equity of $23,000,000 and net cash from continuing financing activities of $22,351,000, supporting the balance sheet and liquidity runway.
Cash and equivalents were robust in 2025, with about $40,402,000 on hand in Q3 2025, providing a cushion for ongoing development and operations.
At Q3 2025, the balance sheet showed a solid base: Total Assets around $159,384,000, Total Equity around $137,415,000, and Total Liabilities around $21,969,000, indicating a strong equity cushion versus liabilities.
Operating expenses remain elevated in 2025 (SG&A $6,701,000; Marketing $23,816,000; R&D $4,815,000 in Q4 2025), reflecting ongoing investments in marketing and product development that may weigh on near-term margins.
Total Operating Income in 2025 Q4 was a small positive amount ($118,000), suggesting the company is moving toward breakeven at the operating level despite higher expense levels.
Cash flow shows variability across quarters: Q4 2025 net cash from continuing operating activities was negative ($5,625,000), whereas Q3 2025 and Q2 2025 showed positive cash generation driven by operating or financing activity, indicating a mixed cash-flow profile going into 2026.
Net income attributable to common shareholders in 2025 Q4 was negative, at approximately ($1,723,000), highlighting ongoing profitability challenges at the bottom line despite top-line and gross-margin strength.

05/27/26 06:06 AM ETAI Generated. May Contain Errors.

Gyre Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Gyre Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Gyre Therapeutics' net income appears to be on a downward trend, with a most recent value of $9.88 million in 2025, falling from -$14.76 million in 2015. The previous period was $17.90 million in 2024. See Gyre Therapeutics' forecast for analyst expectations on what's next for the company.

Gyre Therapeutics' total operating income in 2025 was $11.49 million, based on the following breakdown:

Total Gross Profit: $111.17 million
Total Operating Expenses: $99.69 million

Over the last 10 years, Gyre Therapeutics' total revenue changed from $1.75 million in 2015 to $116.59 million in 2025, a change of 6,562.2%.

Gyre Therapeutics' total liabilities were at $23.85 million at the end of 2025, a 11.7% decrease from 2024, and a 37.4% decrease since 2015.

In the past 10 years, Gyre Therapeutics' cash and equivalents has ranged from $10.26 million in 2016 to $44.35 million in 2021, and is currently $37.07 million as of their latest financial filing in 2025.

Over the last 10 years, Gyre Therapeutics' book value per share changed from 2.75 in 2015 to 1.10 in 2025, a change of -60.0%.

Related Companies

Financial statements for NASDAQ:GYRE last updated on 5/10/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gyre Therapeutics (GYRE) Financials

Financials Breakdown Chart

Key Financial Trends

Gyre Therapeutics Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gyre Therapeutics (GYRE) Financials

Annual Income Statements for Gyre Therapeutics

Quarterly Income Statements for Gyre Therapeutics

Annual Cash Flow Statements for Gyre Therapeutics

Quarterly Cash Flow Statements for Gyre Therapeutics

Annual Balance Sheets for Gyre Therapeutics

Quarterly Balance Sheets for Gyre Therapeutics

Annual Metrics And Ratios for Gyre Therapeutics

Quarterly Metrics And Ratios for Gyre Therapeutics

Financials Breakdown Chart

Key Financial Trends

Gyre Therapeutics Financials - Frequently Asked Questions

When does Gyre Therapeutics' financial year end?

How has Gyre Therapeutics' net income changed over the last 10 years?

What is Gyre Therapeutics' operating income?

How has Gyre Therapeutics' revenue changed over the last 10 years?

How much debt does Gyre Therapeutics have?

How much cash does Gyre Therapeutics have?

How has Gyre Therapeutics' book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools